Bladder Cancer 15-291

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 15-291
Bladder cancers that invade the muscle wall of the bladder have a high risk of returning. Patients with these cancers typically have their bladders removed and are then monitored to see if the cancer comes back. In this study, researchers want to see if the drug atezolizumab can reduce the risk of cancer recurrence after bladder removal surgery for muscle-invasive bladder cancer.

Atezolizumab is a form of immunotherapy. It is designed to improve the immune system's ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating advanced bladder cancer; its use in this study is considered investigational.

Atezolizumab is given intravenously. Patients in this study will be randomly assigned to receive atezolizumab or observation only (no treatment).

Who’s eligible: Patients must have muscle-invasive bladder cancer and have surgery to remove the bladder. Patients may have had chemotherapy or radiation therapy before surgery, but not after surgery. At least 3 weeks must pass between completion of prior therapy and entry into the study. Patients must have declined or must not be eligible to receive adjuvant chemotherapy with cisplatin.

Patients must be able to be walk and do routine activities for more than half of their normal waking hours.

This study is for patients age 18 and older.

Available at: MidState Medical Center, The Hospital of Central Connecticut, Hartford Hospital